Meeting
2022 ASCO Annual Meeting
Adavosertib in combination with carboplatin in advanced TP53-mutated platinum-resistant ovarian cancer.
Authors
Alaa Embaby
Department of Clinical Pharmacology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
Alaa Embaby , Jill Jacqueline Geenen , Joachim Kutzera , Dick Pluim , Marta I. Lopez-Yurda , Jos H. Beijnen , Alwin Huitema , Petronella Witteveen , Neeltje Steeghs , Gijs van Haaften , Marcel A.T.M. van Vugt , Jeroen de Ridder , Frans Opdam
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT01164995
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 5516)
DOI
10.1200/JCO.2022.40.16_suppl.5516
Abstract #
5516
Poster Bd #
395
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study.
First Author: Kathleen N. Moore
Poster
2016 ASCO Annual Meeting
A Phase Ib, Open-Label, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of AZD1775 Monotherapy in Patients with Advanced Solid Tumors: Expansion Cohorts.
First Author: Todd Michael Bauer
Poster
2015 ASCO Annual Meeting
Multicenter randomized Phase II study of AZD1775 plus chemotherapy versus chemotherapy alone in patients with platinum-resistant TP53-mutated epithelial ovarian, fallopian tube, or primary peritoneal cancer.
First Author: Kathleen N. Moore
Poster
2023 ASCO Annual Meeting
Phase 1/1b study of PRGN-3005 autologous UltraCAR-T cells manufactured overnight for infusion next day to advanced stage platinum resistant ovarian cancer patients.
First Author: John B. Liao